hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human models of disease to study new drugs and investigate disease in a safe, controlled environment.
hVIVO has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 48 clinical studies, involving more than 2,300 volunteers for a range of leading industry, governmental and academic clients. However, the hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.
Please note the company changed name from Retroscreen Virology to hVIVO in April 2015, so many of the historical documents here will refer to Retroscreen Virology.
Click here for access to the Company’s Annual and Half-yearly Reports.
General Events and Update Releases
Find out more about hVIVO general event and activity updates here
Company News Releases
Find out more about hVIVO plc’s published Company announcements for investors here
Regulatory News Services
For all regulatory news updates for hVIVO, visit the London Stock Exchange hVIVO (HVO) page here
The Principles of Governance – hVIVO’s Board recognises the importance of good corporate governance not only in the areas of accountability and risk management, but also in enhancing and protecting shareholder value. The Company considers the UK Corporate Governance Code (the “Code”) as a basis for guiding its governance structures. However, it is recognised that some aspects of the Code are not relevant for AIM companies such as hVIVO. The Board seeks to comply with the principles of the Quoted Companies Alliance Corporate Governance Code for Small and Mid-Sized Quoted Companies (the “QCA Code”), which is more applicable for small and medium-sized companies.
Country of incorporation – hVIVO plc (formerly Retroscreen Virology Group plc) is incorporated in England and Wales (Registration number 08008725). All operations are carried out within the United Kingdom.
Takeovers and Mergers – hVIVO is subject to the UK City Code on Takeovers and Mergers.
Audit Committee: Click here for more information.
Remuneration Committee: Click here for more information.
Directors: Click here for more information.
Company’s Advisers: Click here for details.
Articles of Association – please click here Articles of Association
Securities in issue
Click here for more information about number of securities in issue and, insofar as the Company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.
AIM Rule 26
Click here for information to be disclosed in accordance with the London Stock Exchange AIM Rule 26.
You can contact us regarding any investor aspect using the form below. Full contact information is displayed below the form for your reference.
Main Switchboard: Our number for investors and clients is
+44 (0) 20 7756 1300
Main London office and registered business address:
hVIVO Services Limited
Queen Mary BioEnterprises (QMB) Innovation Centre
42 New Road
London E1 2AX